Estée Lauder Q4 FY2026 shows recovery but valuation and leverage still weigh

What happened

Estée Lauder's fiscal Q4 2026 results (reported around August 2026) showed notable improvement, with management citing margin expansion, positive organic sales growth, and broad-based regional gains that extended the stabilization seen earlier in fiscal 2026. This follows the deep reset in fiscal 2025, when the company swung to a $1.1 billion net loss and leverage spiked to roughly 34x net debt/EBITDA, prompting a WAIT rating in our previous analysis. While the Q4 results and the Zacks article highlight continued momentum into fiscal 2027, the financial foundation remains fragile: the balance sheet is still stretched, cash flow generation is volatile, and the stock trades at a triple-digit EV/EBITDA multiple. The reported margin improvement and organic sales growth are positive signals that the PRGP restructuring is gaining traction, but regional gains may be flattered by easy comparisons and ongoing inventory normalization in travel retail and China. Consequently, our thesis shifts only modestly: the recovery is becoming more tangible, but the risk/reward is still unattractive for new capital until leverage trends down and valuation becomes more reasonable.

Implication

The Q4 results suggest that management's PRGP restructuring is delivering the promised margin recovery, and organic sales growth across regions indicates that demand is stabilizing after a severe downturn. However, the company's net debt/EBITDA of roughly 34x and negative interest coverage leave little room for error if the macroeconomic environment deteriorates or if China and travel retail fail to sustain their improvement. With shares trading at over 200x EV/EBITDA and more than 700% above a conservative DCF-derived intrinsic value, the market is already pricing in a rapid and sustained normalization that is far from guaranteed. Even if fiscal 2027 continues the positive trajectory, the current valuation offers minimal margin of safety, and any disappointment in Asia or a stall in margin expansion could lead to a sharp de-rating. Long-term investors may find better opportunities to enter if the company demonstrates consistent free cash flow generation and reduces leverage, but for now, patience is warranted.

Thesis delta

Our stance shifts from a cautious WAIT with high uncertainty to a WAIT with modestly improving fundamentals, as Q4 FY2026 results show tangible progress in margin and organic growth. However, the balance sheet remains highly leveraged and the stock trades at a premium that assumes a flawless multi-year recovery, which is not yet proven. Consequently, we maintain our WAIT rating but acknowledge that the turnaround is gaining credibility, and we will monitor subsequent quarters for sustained free cash flow improvement and deleveraging before considering an upgrade.